On October 25, 2023, Nykode Therapeutics AS closed the transaction. The company amended the terms of the transaction and announced that it has issued 29,549,400 new common shares at a price of NOK 17.10 per share for the gross proceeds of up to NOK 505.29474 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.24 NOK | +2.00% | +0.61% | -38.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.13% | 393M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.46% | 22.18B | |
-16.67% | 21.2B | |
-8.58% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- VACC Stock
- News Nykode Therapeutics
- Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding